Masahiro Sakaguchi,Hiroki Yamaguchi,Yuho Najima,Kensuke Usuki,Toshimitsu Ueki,Iekuni Oh,Sinichiro Mori,Eri Kawata,Nobuhiko Uoshima,Yutaka Kobayashi,Shinichi Kako,Kenji Tajika,Seiji Gomi,Katsuhiro Shono,Kensuke Kayamori,Masao Hagihara,Junya Kanda,Hitoji Uchiyama,Junya Kuroda,Naoyuki Uchida,Yasushi Kubota,Shinya Kimura,Saiko Kurosawa,Nana Nakajima,Atsushi Marumo,Ikuko Omori,Yusuke Fujiwara,Shunsuke Yui,Satoshi Wakita,Kunihito Arai,Tomoaki Kitano,Kazuhiko Kakihana,Yoshinobu Kanda,Kazuteru Ohashi,Takahiro Fukuda,Koiti Inokuchi

Abstract:In the opinion of the European LeukemiaNet (ELN), nucleophosmin member 1 gene mutation (NPM1 mut)-positive acute myeloid leukemia (AML) with an fms-like kinase 3-internal tandem duplication (FLT3-ITD) allele ratio (AR) <0.5 (low AR) has a favorable prognosis, and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the first complete remission (CR1) period is not actively recommended. We studied 147 patients with FLT3-ITD gene mutation-positive AML, dividing them into those with low AR and those with AR of ≥0.5 (high AR), and examined the prognostic impact according to allo-HSCT in CR1. Although FLT3-ITD AR and NPM1 mut are used in the prognostic stratification, we found that NPM1 mut-positive AML with FLT3-ITD low AR was not associated with favorable outcome (overall survival [OS], 41.3%). Moreover, patients in this group who underwent allo-HSCT in CR1 had a significantly more favorable outcome than those who did not (relapse-free survival [RFS] P = .013; OS P = .003). Multivariate analysis identified allo-HSCT in CR1 as the sole favorable prognostic factor (RFS P < .001; OS P < .001). The present study found that prognosis was unfavorable in NPM1 mut-positive AML with FLT3-ITD low AR when allo-HSCT was not carried out in CR1.

Prognostic impact of low allelic ratio FLT3- ITD and NPM1 mutation in acute myeloid leukemia